Form 4: Suvretta Capital Boosts Veradermics Stake

Suvretta Capital Management and affiliated funds significantly increased their beneficial ownership in Veradermics, Inc. through open market purchases in early February 2026.

Summary

• Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., collectively known as the Reporting Persons, acquired additional shares of Veradermics, Inc. common stock.
• The transactions occurred on February 4, 5, and 6, 2026.
• A total of 282,594 shares of common stock were purchased across multiple open market transactions.
• The purchase prices ranged from $33.50 to $40.00 per share, with weighted average prices reported for each block of shares.
• Following these transactions, the Reporting Persons beneficially own a combined total of 4,168,991 shares of Veradermics, Inc. common stock.
• The purchases were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• David Friedman, M.D., a Managing Director and Senior Analyst at Suvretta Capital, serves on the board of directors of Veradermics, Inc., leading to Suvretta Capital and the Funds being deemed directors by deputization.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, given the substantial insider buying by a significant institutional investor and director, indicating high confidence in Veradermics, Inc.'s value proposition.

Positives

• Significant insider buying by a major institutional investor and its affiliates, including a 10% owner and director, signals confidence in Veradermics, Inc.'s future prospects.
• The purchases were executed over several days and at varying price points, suggesting a strategic accumulation rather than a single opportunistic trade.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned investment strategy, which can sometimes be viewed as a more disciplined approach to increasing ownership.

Negatives

• The filing does not contain any explicitly negative information; it solely reports insider purchases.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

StockSavvy.ai notes that significant insider buying, especially by a 10% owner and director, in the biotechnology or pharmaceutical sector can often be interpreted as a strong vote of confidence in a company's pipeline, clinical trial progress, or market potential, particularly when the purchases are substantial and occur over multiple trading days.

Comparison to Industry Standards

• Insider buying of this magnitude by a major institutional investor and director is generally viewed positively, aligning with best practices where management and significant shareholders demonstrate conviction through capital allocation.
• Compared to typical insider transactions, the volume of shares acquired (over 280,000 shares) and the total beneficial ownership (over 4 million shares) by Suvretta Capital and its funds are substantial, indicating a high level of commitment.
• The consistent buying across several days and price points, rather than a single large block, suggests a strategic accumulation strategy, which is often seen as more robust than opportunistic buying.

Corporate Governance

Related Party Transactions

• The transactions involve Suvretta Capital Management, LLC, its affiliated funds (Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.), and Aaron Cowen, who is deemed to control Suvretta Capital. These entities are considered related parties due to their significant ownership and board representation (by deputization) in Veradermics, Inc.

Stakeholder Impact

• Shareholders: The significant insider buying by a major institutional investor and director could instill greater confidence among existing shareholders and attract new investors, potentially leading to positive share price movement.
• Management: The increased stake by a key investor and board member reinforces alignment between management and a significant shareholder, potentially fostering a more stable and supportive governance environment.

Key Dates

Recommendation

The substantial and consistent insider buying by Suvretta Capital Management, a 10% owner and director (by deputization), across multiple days and price points, signals strong conviction in Veradermics, Inc.'s valuation and future prospects. Such significant capital allocation by a sophisticated institutional investor, especially one with board representation, typically precedes positive developments or reflects an undervalued asset. This action provides a compelling reason for investors to consider a 'strong buy' position, assuming no other adverse information is available.

Keywords

Veradermics, MANE, Suvretta Capital Management, Insider Buying, Form 4, Equity Purchase, Institutional Investor, Biotechnology, Pharmaceuticals